Tempest Therapeutics, Inc.
TPST
$1.92
-$0.02-1.03%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.40% | 1.10% | 9.35% | -8.94% | -4.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -70.71% | -65.91% | -16.86% | 37.15% | 85.23% |
| Operating Income | 70.71% | 65.91% | 16.86% | -37.15% | -85.23% |
| Income Before Tax | 70.89% | 66.74% | 17.76% | -37.40% | -84.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 70.89% | 66.74% | 17.76% | -37.40% | -84.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 70.89% | 66.74% | 17.76% | -37.40% | -84.47% |
| EBIT | 70.71% | 65.91% | 16.86% | -37.15% | -85.23% |
| EBITDA | 71.07% | 66.22% | 16.21% | -37.81% | -86.69% |
| EPS Basic | 81.29% | 85.13% | 62.50% | 31.64% | 12.31% |
| Normalized Basic EPS | 81.29% | 85.13% | 62.50% | 31.64% | 12.31% |
| EPS Diluted | 81.29% | 85.13% | 62.50% | 31.64% | 12.31% |
| Normalized Diluted EPS | 81.29% | 85.13% | 62.50% | 31.64% | 12.31% |
| Average Basic Shares Outstanding | 55.62% | 123.67% | 119.28% | 101.00% | 110.35% |
| Average Diluted Shares Outstanding | 55.62% | 123.67% | 119.28% | 101.00% | 110.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |